Back to Search
Start Over
Effective management of severe cutaneous mastocytosis in young children with omalizumab (Xolair®).
- Source :
- Clinical & Experimental Dermatology; Jul2018, Vol. 43 Issue 5, p573-576, 4p, 1 Color Photograph, 1 Graph
- Publication Year :
- 2018
-
Abstract
- Summary: Omalizumab (Xolair<superscript>®</superscript>) is an anti‐IgE monoclonal antibody, which may benefit adults with systemic mastocytosis. We report effective treatment with omalizumab in two toddlers with severe diffuse cutaneous mastocytosis. Our cases offer preliminary evidence to support the safe use of omalizumab in paediatric patients with cutaneous mastocytosis. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 03076938
- Volume :
- 43
- Issue :
- 5
- Database :
- Complementary Index
- Journal :
- Clinical & Experimental Dermatology
- Publication Type :
- Academic Journal
- Accession number :
- 130341922
- Full Text :
- https://doi.org/10.1111/ced.13408